HBF-0259

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug NameHBF-0259
Drug Alias Namehepatitis B surface antigen inhibitors (Institute for Hepatitis & Virus Research/Enantigen Therapeutics)disubstituted TTPs (Pharmabridge)hepatitis B virus surface antigen inhibitors (Pharmabridge)disubstituted tetrahydro-triazolo-pyrimidines (Pharmabridge)PBHBV-001 +[8] 
ClassificationSmall molecules
Mechanisms of ActionHBsAg inhibitors
TargetsHepatitis B Surface Antigens
Therapy Area/IndicationsHepatitis B
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBaruch S. Blumberg Institute
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEnantigen Therapeutics IncOnCore Biopharma IncRoivant Sciences Ltd +[5] 
Active IndicationsN/A
Inactive IndicationsHepatitis B

Other Information

ATC CodeN/A
Related LinksN/A